Invest in the first Chinese pharmaceutical company to list on the ASX:

Haixi Pharmaceutical International Holdings Limited ASX: HXP

Dear Readers,

I invite you to participate in the initial public offering of the first Chinese pharmaceutical company to list on the ASX, Haixi Pharmaceutical International Holdings Limited.

The Company

Established in 1995, Haixi is a long-standing, highly recognised and respected brand in the pharmaceutical industry in China. The Company is engaged in the business of manufacturing, sales, R&D of State Food and Drug Administration (SFDA) approved pharmaceutical products, which includes ointment and medicinal creams treating pains, swelling and itching, as well as tablets, capsules and liquids.

Growth Strategy


  • Invested in a new factory expected to be operational in 2018;
  • To significantly increase production range and quantity by adding new production lines and launching 20 new products.


  • Plans to expand into the Australian market and intends to acquire or invest in Australian companies in the pharmaceutical sector;
  • Seeking opportunity to build raw materials plantation and development base to ensure the high quality of its raw material of its end products.

Investment Highlights

  • Substantial increasing profits and assets with high margins;
  • First Chinese pharmaceutical company to be listed on the ASX;
  • Long-standing brand recognition with 20 years history;
  • High dividend payout ratio planned at 50% of NPAT, payable twice a year;
  • Value investment at a P/E lower than sector average on ASX and HKEX;
  • Plans to expand into the Australian market and intends to acquire or invest in Australian companies in the pharmaceutical sector;
  • China is the world's second largest market for pharmaceuticals.

Key Offer Statistics

  • Amount to be raised: Up to $30m
  • Offer Price per share: $0.50
  • Minimum investment: $2,000.00
  • Maximum number of shares available under the offer: 60m
  • Total number of shares (and equivalent shares) on issue as at the date of the Prospectus: 200m
  • Number of shares on issue following the Offer based on maximum subscription: 260m
  • Market capitalisation at Listing based on maximum subscription: $130m
  • Post IPO P/E based on maximum subscription: 12.29x
  • ASX sector average P/E based on maximum subscription: 15.75x
  • HKEX sector average P/E based on maximum subscription: 17x
  • Offer opens: 21 July 2017
  • Offer closes: 29 September 2017
  • Trading expected to commence on the ASX: 5 October 2017

BlueMount Capital, with offices in Australia and Asia, is the Australian lead manager for the offer.

Investors interested in applying for shares will need to complete the Application Form in the Prospectus. Investors should consider the Prospectus in its entirety and obtain professional advice before deciding whether to invest in the Company. 

The offer is now open and the Prospectus can be downloaded from BlueMount Capital's website at Alternatively, please contact us via email or phone +61 7 3160 2840 to obtain a hard or soft copy of the prospectus. 

We look forward to hearing from you!

Managing Director

Providing Corporate Advice, Funding Strategies and Exits for profitable expanding Companies.

Haixi Pharmaceutical International Holdings Limited is the issuer of the securities on offer under the Prospectus. The Prospectus is available and can be obtained by visiting the BlueMount website:

The offers of the securities will be made in, or accompanied by, a copy of the Prospectus and a person should consider the Prospectus before deciding whether to acquire the securities and anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the Prospectus.



BlueMount Capital (Qld) Pty Ltd ACN 147 942 603 

Authorised Representative for AFSL 456663 
Level 5, 15 Astor Terrace, Spring Hill QLD 4000
Telephone +61 7 3160 2840 

You are receiving this email because you are a valued contact and have provided us with your details in the past. If you ever wish to change your personal details simply update your profile, or to unsubscribe, click the unsubscribe link located at the bottom of any of our emails. 

Not interested? Unsubscribe | Update profile
BlueMount Capital (QLD) Pty Ltd | Level 5 | 15 Astor Terrace | Spring Hill QLD 4000 | Australia